I share your frustration with the apparent extende
Post# of 72447
(Total Views: 286)
Posted On: 07/08/2017 2:31:42 PM
I share your frustration with the apparent extended undervaluation of this pipeline. However, the reason why you can come up with no other reason for the stock price decline aside from naked shorting is your investment in the theory. Much like you can't accept that you were early to CTIX, you also can't accept that you were wrong about the naked shorting issue.
Now, there are clearly market making games being played here but with the CUSIP change I am convinced there is no significant outstanding naked short position. The idea that they could just re-short doesn't hold water. Why would AMBS fly as Drano demonstrated if the same could be done there? The simple answer is that there isn't much naked shorting going on.
A low cash balance, listing on a low-quality exchange, line of credit tied to the stock price, and a share price which has flirted with $1 for nearly a year all prevent lots of big money from taking a position in our stock. Combine that with most of the believers, ourselves included, getting hammered by Mako/Rosen and you're left with very little ability to move the stock back up. On top of all that non-pipeline crap we had the following issues with the trials:
1. The indefinite hold on B-ABSSSI phase 3 initiation.
2. The necessity of a Prurisol phase 2B.
3. The extension of the original B-OM phase 2 completion date by about a year.
4. Lack of funding for the K AML Phase 2.
All of this compounded made it clear that this had become a 2017/2018 story. It became apparent that we need a strong P2B result or a partnership to rescue the stock price. So there's a number of reasons why the stock price hasn't gone where you think it should have.
Fortunately, that time for the potential turnaround is nearly upon us. The wait has been long but it has given us plenty of time to take our position. We are now due to see some results which can right this ship and bring us to the next leg of our journey. I have faith that we will succeed and bring new cures the market and a hearty return to true investors of IPIX.
Go IPIX!
P.S. Nope. Not a multi-alias or a basher. Just a long like you.
Now, there are clearly market making games being played here but with the CUSIP change I am convinced there is no significant outstanding naked short position. The idea that they could just re-short doesn't hold water. Why would AMBS fly as Drano demonstrated if the same could be done there? The simple answer is that there isn't much naked shorting going on.
A low cash balance, listing on a low-quality exchange, line of credit tied to the stock price, and a share price which has flirted with $1 for nearly a year all prevent lots of big money from taking a position in our stock. Combine that with most of the believers, ourselves included, getting hammered by Mako/Rosen and you're left with very little ability to move the stock back up. On top of all that non-pipeline crap we had the following issues with the trials:
1. The indefinite hold on B-ABSSSI phase 3 initiation.
2. The necessity of a Prurisol phase 2B.
3. The extension of the original B-OM phase 2 completion date by about a year.
4. Lack of funding for the K AML Phase 2.
All of this compounded made it clear that this had become a 2017/2018 story. It became apparent that we need a strong P2B result or a partnership to rescue the stock price. So there's a number of reasons why the stock price hasn't gone where you think it should have.
Fortunately, that time for the potential turnaround is nearly upon us. The wait has been long but it has given us plenty of time to take our position. We are now due to see some results which can right this ship and bring us to the next leg of our journey. I have faith that we will succeed and bring new cures the market and a hearty return to true investors of IPIX.
Go IPIX!
P.S. Nope. Not a multi-alias or a basher. Just a long like you.
(4)
(2)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.